
|Articles|January 3, 2014
Big Pharma's Second Life
Drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at a CBI event in The Triangle.
Advertisement
Can big pharma solve its fixed cost problem by going virtual? Not entirely, but drug companies can get more out of their CRO partners by treating them less like avatars and more like equals, according to conference-goers at CBI's Sponsor/CRO Systems & Business Process Integration conference in The Triangle.
Check out the
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
From Participation to Understanding: Reframing Engagement in Clinical Trials
2
Beyond Compliance: NetraMark's Joseph Geraci, PhD, on Making AI-Driven Patient Subgroups Explainable
3
ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis
4
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
5



